307 related articles for article (PubMed ID: 22863764)
1. Predicted effects of treatment for HCV infection vary among European countries.
Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
[TBL] [Abstract][Full Text] [Related]
2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
3. [Chronic hepatitis C].
Grammatikos G; Sarrazin C
Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C and hepatitis B-related mortality in Spain.
García-Fulgueiras A; García-Pina R; Morant C; García-Ortuzar V; Génova R; Alvarez E
Eur J Gastroenterol Hepatol; 2009 Aug; 21(8):895-901. PubMed ID: 19357523
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
Giannini EG; Marenco S; Fazio V; Pieri G; Savarino V; Picciotto A
Liver Int; 2012 Aug; 32(7):1113-9. PubMed ID: 22471814
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.
Larsen C; Bousquet V; Delarocque-Astagneau E; Pioche C; Roudot-Thoraval F; ; ; Desenclos JC
J Med Virol; 2010 Oct; 82(10):1647-54. PubMed ID: 20827760
[TBL] [Abstract][Full Text] [Related]
7. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.
Lai MY
Intervirology; 2006; 49(1-2):91-5. PubMed ID: 16166795
[TBL] [Abstract][Full Text] [Related]
8. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
11. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
12. Current status of hepatitis C virus infection in Korea.
Suh DJ; Jeong SH
Intervirology; 2006; 49(1-2):70-5. PubMed ID: 16166792
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
Niederau C
Med Klin (Munich); 2001 Oct; 96(10):599-607. PubMed ID: 11715332
[TBL] [Abstract][Full Text] [Related]
15. New trends in hepatitis C management.
Mallet V; Vallet-Pichard A; Pol S
Presse Med; 2010 Apr; 39(4):446-51. PubMed ID: 20074903
[TBL] [Abstract][Full Text] [Related]
16. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
[TBL] [Abstract][Full Text] [Related]
17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
18. Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H; Dore GJ; Ward JW
J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C and hepatocellular carcinoma.
Fassio E
Ann Hepatol; 2010; 9 Suppl():119-22. PubMed ID: 20714008
[TBL] [Abstract][Full Text] [Related]
20. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
Deuffic-Burban S; Boursier J; Leroy V; Yazdanpanah Y; Castera L; Mathurin P
J Hepatol; 2017 Feb; 66(2):304-312. PubMed ID: 27743987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
